Skip to main content
Search
Audio Interview

The state of the art in secondary pharmacology

Published on July 31, 2025   19 min

Other Talks in the Playlist: Research and Clinical Interviews

Please wait while the transcript is being prepared...
0:00
Interviewer: Today, we are joined by Dr. Jean-Pierre Valentin, Senior Director and Head of Investigative Toxicology at UCB, to discuss his 2024 paper together with colleagues in Nature Reviews Drug Discovery. The paper presents a survey on the current state of secondary pharmacology across the industry and proposes best practices for its implementation. Notably, the Safety Pharmacology Society officially recognized this paper as the most impactful safety pharmacology publication of 2024. Dr. Jean-Pierre Valentin, thank you very much for joining us today. Dr. Valentin: Thank you for the kind invitation. Interviewer: Can we start by defining what secondary pharmacology is? Dr. Valentin: Yes. Secondary pharmacology refers to the investigation of a drug's interaction with molecular targets other than its intended therapeutic target. An official definition [inaudible] back in 2000 in the ICH guideline on safety pharmacology. The document states that secondary pharmacodynamic studies are those that investigate the mode of action and/or effect of a substance, not related to its desired therapeutic targets. This comprehensive screening approach employs in vitro biochemical and cellular assays to evaluate potential interaction with various biological targets, including, for example, G protein-coupled receptors, enzymes including kinases, nuclear hormone receptors, ion channels and transporters. The primary purpose is to detect

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

The state of the art in secondary pharmacology

Embed in course/own notes